{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:43:01Z","timestamp":1787002981879,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41416-019-0426-5","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T20:03:49Z","timestamp":1552507429000},"page":"848-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk"],"prefix":"10.1038","volume":"120","author":[{"given":"Tsuyoshi","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Yurgelun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Morales-Oyarvide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Babic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Rubinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Giannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmie","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir J.","family":"Stampfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Giovannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Wolpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"426_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"426_CR2","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D. & Biankin, A. V. et al. Pancreatic cancer. Nat. Rev. Dis. Prim. 2, 16022 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"426_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/jnci\/djp466","volume":"102","author":"KA Brune","year":"2010","unstructured":"Brune, K. A., Lau, B., Palmisano, E., Canto, M., Goggins, M. G. & Hruban, R. H. et al. Importance of age of onset in pancreatic cancer kindreds. J. Natl. Cancer Inst. 102, 119\u2013126 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"426_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1023\/A:1026580131793","volume":"11","author":"SS Coughlin","year":"2000","unstructured":"Coughlin, S. S., Calle, E. E., Patel, A. V. & Thun, M. J. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11, 915\u2013923 (2000).","journal-title":"Cancer Causes Control"},{"key":"426_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ijc.10863","volume":"103","author":"K Hemminki","year":"2003","unstructured":"Hemminki, K. & Li, X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int. J. Cancer 103, 525\u2013530 (2003).","journal-title":"Int. J. Cancer"},{"key":"426_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/ijc.25148","volume":"127","author":"EJ Jacobs","year":"2010","unstructured":"Jacobs, E. J., Chanock, S. J., Fuchs, C. S., Lacroix, A., McWilliams, R. R. & Steplowski, E. et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int. J. Cancer 127, 1421\u20131428 (2010).","journal-title":"Int. J. Cancer"},{"key":"426_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canep.2016.10.005","volume":"45","author":"A Schulte","year":"2016","unstructured":"Schulte, A., Pandeya, N., Fawcett, J., Fritschi, L., Klein, K. & Risch, H. A. et al. Association between family cancer history and risk of pancreatic cancer. Cancer Epidemiol. 45, 145\u2013150 (2016).","journal-title":"Cancer Epidemiol."},{"key":"426_CR8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s10552-009-9339-6","volume":"20","author":"EJ Jacobs","year":"2009","unstructured":"Jacobs, E. J., Rodriguez, C., Newton, C. C., Bain, E. B., Patel, A. V. & Feigelson, H. S. et al. Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes Control 20, 1261\u20131269 (2009).","journal-title":"Cancer Causes Control"},{"key":"426_CR9","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1158\/1055-9965.EPI-09-0557","volume":"18","author":"L Wang","year":"2009","unstructured":"Wang, L., Brune, K. A., Visvanathan, K., Laheru, D., Herman, J. & Wolfgang, C. et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 18, 2829\u20132834 (2009).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"426_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cncr.21166","volume":"104","author":"RR McWilliams","year":"2005","unstructured":"McWilliams, R. R., Rabe, K. G., Olswold, C., De Andrade, M. & Petersen, G. M. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 104, 388\u2013394 (2005).","journal-title":"Cancer"},{"key":"426_CR11","doi-asserted-by":"crossref","unstructured":"Antwi, S. O., Fagan, S. E., Chaffee, K. G., Bamlet, W. R., Hu, C., & Polley, E. C. et al. Risk of different cancers among first-degree relatives of pancreatic cancer patients: influence of probands\u2019 susceptibility gene mutation status. J. Natl Cancer Inst. (2018).","DOI":"10.1093\/jnci\/djx272"},{"key":"426_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/gim.2014.153","volume":"17","author":"DB Zhen","year":"2015","unstructured":"Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G. & Goggins, M. G. et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet. Med. 17, 569\u2013577 (2015).","journal-title":"Genet. Med."},{"key":"426_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171202","volume":"324","author":"S Jones","year":"2009","unstructured":"Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X. & Parsons, D. W. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).","journal-title":"Science"},{"key":"426_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.hoc.2015.04.007","volume":"29","author":"GM Petersen","year":"2015","unstructured":"Petersen, G. M. Familial pancreatic adenocarcinoma. Hematol. Oncol. Clin. North. Am. 29, 641\u2013653 (2015).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"426_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","volume":"6","author":"NJ Roberts","year":"2016","unstructured":"Roberts, N. J., Norris, A. L., Petersen, G. M., Bondy, M. L., Brand, R. & Gallinger, S. et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 6, 166\u2013175 (2016).","journal-title":"Cancer Discov."},{"key":"426_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Breast Cancer Linkage Consortium.","year":"1999","unstructured":"Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91, 1310\u20131316 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"426_CR17","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson, D. & Easton, D. F. Cancer Incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94, 1358\u20131365 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"426_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mc.20855","volume":"51","author":"AP Klein","year":"2012","unstructured":"Klein, A. P. Genetic susceptibility to pancreatic cancer. Mol. Carcinog. 51, 14\u201324 (2012).","journal-title":"Mol. Carcinog."},{"key":"426_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ajg.2014.435","volume":"110","author":"S Syngal","year":"2015","unstructured":"Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L. & Burt, R. W. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am. J. Gastroenterol. 110, 223\u2013262 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"426_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1200\/JCO.2011.39.5590","volume":"30","author":"AK Win","year":"2012","unstructured":"Win, A. K., Young, J. P., Lindor, N. M., Tucker, K. M., Ahnen, D. J. & Young, G. P. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol. 30, 958\u2013964 (2012).","journal-title":"J. Clin. Oncol."},{"key":"426_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3748\/wjg.v23.i6.935","volume":"23","author":"H Matsubayashi","year":"2017","unstructured":"Matsubayashi, H., Takaori, K., Morizane, C., Maguchi, H., Mizuma, M. & Takahashi, H. et al. Familial pancreatic cancer: Concept, management and issues. World J. Gastroenterol. 23, 935\u2013948 (2017).","journal-title":"World J. Gastroenterol."},{"key":"426_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1055-9965.EPI-12-0195","volume":"22","author":"E Mocci","year":"2013","unstructured":"Mocci, E., Milne, R. L., Mendez-Villamil, E. Y., Hopper, J. L., John, E. M. & Andrulis, I. L. et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol. Biomark. Prev. 22, 803\u2013811 (2013).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"426_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/jnci\/92.15.1260","volume":"92","author":"A Borg","year":"2000","unstructured":"Borg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M. & Masback, A. et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J. Natl Cancer Inst. 92, 1260\u20131266 (2000).","journal-title":"J. Natl Cancer Inst."},{"key":"426_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5835","volume":"5","author":"S Carmi","year":"2014","unstructured":"Carmi, S., Hui, K. Y., Kochav, E., Liu, X., Xue, J. & Grady, F. et al. Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nat. Commun. 5, 4835 (2014).","journal-title":"Nat. Commun."},{"key":"426_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature09103","volume":"466","author":"DM Behar","year":"2010","unstructured":"Behar, D. M., Yunusbayev, B., Metspalu, M., Metspalu, E., Rosset, S. & Parik, J. et al. The genome-wide structure of the Jewish people. Nature 466, 238\u2013242 (2010).","journal-title":"Nature"},{"key":"426_CR26","doi-asserted-by":"publisher","first-page":"16222","DOI":"10.1073\/pnas.1004381107","volume":"107","author":"SM Bray","year":"2010","unstructured":"Bray, S. M., Mulle, J. G., Dodd, A. F., Pulver, A. E., Wooding, S. & Warren, S. T. Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population. Proc. Natl Acad. Sci. USA 107, 16222\u201316227 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"426_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cncr.26191","volume":"118","author":"ZK Stadler","year":"2012","unstructured":"Stadler, Z. K., Salo-Mullen, E., Patil, S. M., Pietanza, M. C., Vijai, J. & Saloustros, E. et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 118, 493\u2013499 (2012).","journal-title":"Cancer"},{"key":"426_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","volume":"28","author":"KA Metcalfe","year":"2010","unstructured":"Metcalfe, K. A., Poll, A., Royer, R., Llacuachaqui, M., Tulman, A. & Sun, P. et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J. Clin. Oncol. 28, 387\u2013391 (2010).","journal-title":"J. Clin. Oncol."},{"key":"426_CR29","first-page":"505","volume":"60","author":"D Abeliovich","year":"1997","unstructured":"Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G. & Sagi, M. et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet. 60, 505\u2013514 (1997).","journal-title":"Am. J. Hum. Genet."},{"key":"426_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cge.12529","volume":"87","author":"G Ponti","year":"2015","unstructured":"Ponti, G., Castellsague, E., Ruini, C., Percesepe, A. & Tomasi, A. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome. Clin. Genet. 87, 507\u2013516 (2015).","journal-title":"Clin. Genet."},{"key":"426_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1158\/1055-9965.EPI-10-1196","volume":"20","author":"RC Eldridge","year":"2011","unstructured":"Eldridge, R. C., Gapstur, S. M., Newton, C. C., Goodman, M., Patel, A. V. & Jacobs, E. J. Jewish ethnicity and pancreatic cancer mortality in a large U.S. cohort. Cancer Epidemiol. Biomark. Prev. 20, 691\u2013698 (2011).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"426_CR32","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1002\/cncr.29664","volume":"121","author":"EE Salo-Mullen","year":"2015","unstructured":"Salo-Mullen, E. E., O\u2019Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A. & Yu, K. H. et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 121, 4382\u20134388 (2015).","journal-title":"Cancer"},{"key":"426_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10689-004-9549-8","volume":"3","author":"HT Lynch","year":"2004","unstructured":"Lynch, H. T., Deters, C. A., Lynch, J. F. & Brand, R. E. Familial pancreatic carcinoma in Jews. Fam. Cancer 3, 233\u2013240 (2004).","journal-title":"Fam. Cancer"},{"key":"426_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-015-3340-4","volume":"150","author":"Y Laitman","year":"2015","unstructured":"Laitman, Y., Keinan Boker, L., Liphsitz, I., Weissglas-Volkov, D., Litz-Philipsborn, S. & Schayek, H. et al. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 150, 631\u2013635 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"426_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.seminoncol.2014.12.002","volume":"42","author":"TP Yeo","year":"2015","unstructured":"Yeo, T. P. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin. Oncol. 42, 8\u201318 (2015).","journal-title":"Semin. Oncol."},{"key":"426_CR36","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero, M. A., Malafa, M. P., Al-Hawary, M., Asbun, H., Bain, A. & Behrman, S. W. et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 1028\u20131061 (2017).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"426_CR37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S1470-2045(08)70106-2","volume":"9","author":"DS Michaud","year":"2008","unstructured":"Michaud, D. S., Liu, Y., Meyer, M., Giovannucci, E. & Joshipura, K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol. 9, 550\u2013558 (2008).","journal-title":"Lancet Oncol."},{"key":"426_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/oxfordjournals.aje.a117191","volume":"140","author":"JW Rich-Edwards","year":"1994","unstructured":"Rich-Edwards, J. W., Corsano, K. A. & Stampfer, M. J. Test of the national death index and equifax nationwide death search. Am. J. Epidemiol. 140, 1016\u20131019 (1994).","journal-title":"Am. J. Epidemiol."},{"key":"426_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa, T., Wood, L. D., Itoi, T. & Takaori, K. Pancreatic cancer. Lancet 388, 73\u201385 (2016).","journal-title":"Lancet"},{"key":"426_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10689-008-9214-8","volume":"8","author":"J Permuth-Wey","year":"2009","unstructured":"Permuth-Wey, J. & Egan, K. M. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam. Cancer 8, 109\u2013117 (2009).","journal-title":"Fam. Cancer"},{"key":"426_CR41","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M. & Roos-Blom, M. J. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"426_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant, R. C., Selander, I., Connor, A. A., Selvarajah, S., Borgida, A. & Briollais, L. et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148, 556\u2013564 (2015).","journal-title":"Gastroenterology"},{"key":"426_CR43","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.clinthera.2016.03.017","volume":"38","author":"ML Underhill","year":"2016","unstructured":"Underhill, M. L., Germansky, K. A. & Yurgelun, M. B. Advances in hereditary colorectal and pancreatic cancers. Clin. Ther. 38, 1600\u20131621 (2016).","journal-title":"Clin. Ther."},{"key":"426_CR44","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1055-9965.EPI-17-0211","volume":"26","author":"S Lindstrom","year":"2017","unstructured":"Lindstrom, S., Finucane, H., Bulik-Sullivan, B., Schumacher, F. R., Amos, C. I. & Hung, R. J. et al. Quantifying the genetic correlation between multiple cancer types. Cancer Epidemiol. Biomark. Prev. 26, 1427\u20131435 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"426_CR45","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1086\/345075","volume":"71","author":"WD Foulkes","year":"2002","unstructured":"Foulkes, W. D., Thiffault, I., Gruber, S. B., Horwitz, M., Hamel, N. & Lee, C. et al. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am. J. Hum. Genet. 71, 1395\u20131412 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"426_CR46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1399-0004.2010.01594.x","volume":"79","author":"L Raskin","year":"2011","unstructured":"Raskin, L., Schwenter, F., Freytsis, M., Tischkowitz, M., Wong, N. & Chong, G. et al. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. Clin. Genet. 79, 512\u2013522 (2011).","journal-title":"Clin. Genet."},{"key":"426_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jama.2011.955","volume":"306","author":"A Ziogas","year":"2011","unstructured":"Ziogas, A., Horick, N. K., Kinney, A. Y., Lowery, J. T., Domchek, S. M. & Isaacs, C. et al. Clinically relevant changes in family history of cancer over time. JAMA 306, 172\u2013178 (2011).","journal-title":"JAMA"},{"key":"426_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jama.2011.980","volume":"306","author":"LS Acheson","year":"2011","unstructured":"Acheson, L. S. Recording, interpreting, and updating the family history of cancer: implications for cancer prevention. JAMA 306, 208\u2013210 (2011).","journal-title":"JAMA"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0426-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:04:32Z","timestamp":1684602272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0426-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0426-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.S.F. declares consulting for Agios Inc., Bain Capital L.P., Bayer A.G., Celgene Inc., Dicerna Inc., Eli Lilly, Entrinsic Health Solutions Inc., Five Prime Therapeutics Inc., Genentech Inc., Gilead Sciences Inc., KEW Inc., Merck Inc., Merrimack Pharmaceuticals Inc., Pfizer Inc., Sanofi Inc., Taiho Ltd., and Unum Therapeutics Inc. He also serves as a director for CytomX Therapeutics Inc. and owns unexercised stock options for CytomX Therapeutics Inc. and Entrinsic Health Solutions Inc. B.M.W. declares research funding from Celgene Inc., and consulting for BioLineRx Ltd., G1 Therapeutics Inc., and GRAIL Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The datasets used and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Informed consent was obtained from all participants at study enrolment, and the HPFS was approved by the institutional review board at Harvard T.H. Chan School of Public Health (Boston, MA, USA). The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}